Imatinib and dasatinib are tyrosine kinase inhibitors that inhibit the bcr-abl and c-kit tyrosine kinase proteins. Bcr-abl is encoded by the Philadelphia chromosome, which is a t(9;22) fusion gene in CML. Therefore, since they inhibit bcr-abl, imatinib and dasatinib are effective in targeting neoplastic cells in CML. Finally, patients taking imatinib and dasatinib may experience fluid retention as a potential side effect.
- Imatinib, Dasatinib
- Tyrosine kinase inhibitor of bcr-abl and c-kit
- Bcr-abl encoded by the Philadelphia chromosome t(9;22) fusion gene of CML
- Clinical Use
- GI stromal tumors (GIST)
- Adverse Effects
- Fluid retention